Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III study of NBI-74788 for the treatment of adult congenital adrenal hyperplasia (CAH)

Next Previous
Trial Profile

A Phase III study of NBI-74788 for the treatment of adult congenital adrenal hyperplasia (CAH)

Planning
Phase of Trial: Phase III

Latest Information Update: 06 Jan 2019

At a glance

  • Drugs NBI 74788 (Primary)
  • Indications Congenital adrenal hyperplasia
  • Focus Registrational; Therapeutic Use
  • Sponsors Neurocrine Biosciences

    • Most Recent Events

    • 06 Jan 2019 According to a Neurocrine Biosciences media release, this pivotal study initiation for CAH (adults) is expected in 2H 2019 and pending U.S. Food and Drug Administration (FDA) discussion in Q2.
    • 10 Jan 2018 New trial record
    • 07 Jan 2018 According to a Neurocrine Biosciences media release, the company plans to initiate this study in 2H 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top